Lipoxin A4 and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy
Lipoxin A4 and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy
复制标题
DOI：
10.1016/j.jcf.2008.04.002
复制
发表时间：
2008-11-01
影响因子：
5.2
通讯作者：
Urbach, Valerie
中科院分区：
文献类型：
--
作者：
Chiron, Raphael;Grumbach, Y. Yael;Urbach, Valerie
抗生素主要用于囊性纤维化（CF）呼吸恶化。抗生素对患者炎症特征的影响已被证明，但仍存在争议。脂氧素A（4）（LXA（4））是一种脂质介质，据报道在缓解气道炎症中发挥重要作用。本研究的目的是调查抗生素治疗对CF患者气道中LXA（4）和IL-8水平的影响。方法：18名CF患者（7名女性，中位年龄20岁，范围8 - 47岁）在肺恶化期间连续在Montpellier的CF中心入院接受抗生素治疗。在抗生素治疗前后，所有患者均进行肺功能测定（FEV 1和FVC）、细菌培养和肺内细胞计数。结果：经抗生素治疗后，FEV_1和FVC均明显改善。虽然中性粒细胞计数和IL-8水平下降，但抗生素治疗后LXA（4）水平显着增加，并且与IL-8水平呈负相关。总之，我们报告了抗生素治疗与CF痰中炎症标志物之间的相关性。我们的数据为抗生素增加抗炎脂质介质LXA浓度的新作用提供了证据（4）。(C)2008年欧洲囊性纤维化协会。出版社：Elsevier B.V版权所有。
Antibiotics are largely prescribed for cystic fibrosis (CF) respiratory exacerbations. Effects of antibiotics on the inflammatory profile of the patients have been shown but remain controversial. Lipoxin A(4) (LXA(4)) is a lipid mediator, reported to play a central role in resolving airway inflammation. The aim of the study was to investigate the consequences of antibiotherapy on LXA(4) and IL-8 levels in CF patients' airways.Methods: Eighteen CF patients (7 females, median age 20, range 8 to 47 years) consecutively admitted at the CF center of Montpellier for antibiotics during pulmonary exacerbation, were enrolled. Before and after antibiotics, all patients underwent spirometry (FEV1 and FVC), bacterial cultures and cell counts in sputa. IL-8 and LXA(4) concentrations were determined in sputum samples by the median of immunometric assays.Results: As previously reported, after antibiotics therapy, FEV1 and FVC significantly improved. While neutrophil cell counts and IL-8 levels decreased, the LXA(4) levels significantly increased after antibiotics therapy and were inversely correlated with IL-8 levels.In conclusion, we reported a correlation between antibiotics treatments and inflammatory markers in CF sputum. Our data provide evidences for a novel effect of antibiotics increasing the concentration of the anti-inflammatory lipid mediator LXA(4). (C) 2008 European Cystic Fibrosis Society. Published by Elsevier B.V All rights reserved.